ATE509019T1 - Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten - Google Patents
Benzodiazepinspirohydantoine als cgrp- rezeptorantagonistenInfo
- Publication number
- ATE509019T1 ATE509019T1 AT04749375T AT04749375T ATE509019T1 AT E509019 T1 ATE509019 T1 AT E509019T1 AT 04749375 T AT04749375 T AT 04749375T AT 04749375 T AT04749375 T AT 04749375T AT E509019 T1 ATE509019 T1 AT E509019T1
- Authority
- AT
- Austria
- Prior art keywords
- pirohydantoins
- benzodiazepine
- receptor antagonists
- cgrp receptor
- cgrp
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title 1
- 229940049706 benzodiazepine Drugs 0.000 title 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45561103P | 2003-03-14 | 2003-03-14 | |
| PCT/US2004/007715 WO2004087649A2 (en) | 2003-03-14 | 2004-03-10 | Benodiazepine spirohydantoin cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE509019T1 true ATE509019T1 (de) | 2011-05-15 |
Family
ID=33131664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04749375T ATE509019T1 (de) | 2003-03-14 | 2004-03-10 | Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7205293B2 (de) |
| EP (1) | EP1606286B1 (de) |
| JP (1) | JP4584914B2 (de) |
| AT (1) | ATE509019T1 (de) |
| AU (1) | AU2004226018B2 (de) |
| CA (1) | CA2519515A1 (de) |
| WO (1) | WO2004087649A2 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7569578B2 (en) | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| CA2579221A1 (en) * | 2004-09-08 | 2006-03-16 | Merck & Co., Inc. | Monocyclic anilide spirolactam cgrp receptor antagonists |
| CA2580020A1 (en) | 2004-09-09 | 2006-03-23 | Ian M. Bell | Aryl spirolactam cgrp receptor antagonists |
| ATE518852T1 (de) * | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
| AU2005285109B2 (en) | 2004-09-13 | 2011-03-03 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
| WO2007016087A2 (en) | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Heterocyclic benzodiazepine cgrp receptor antagonists |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| SI3045182T1 (en) | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| CA2629406A1 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin aryl cgrp receptor antagonists |
| CA2629421A1 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin tricyclic cgrp receptor antagonists |
| WO2007061677A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| EP1951042B1 (de) | 2005-11-18 | 2012-10-10 | Merck Sharp & Dohme Corp. | Spirolactam tricyclische cgrp-rezeptor-antagonisten |
| WO2007130927A2 (en) | 2006-05-02 | 2007-11-15 | Bristol-Myers Squibb Company | Condensed tricyclic compounds as cgrp-receptor antagonists |
| US7470680B2 (en) | 2006-05-03 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| WO2008020902A1 (en) * | 2006-05-09 | 2008-02-21 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| CA2658573A1 (en) * | 2006-07-21 | 2008-01-24 | Vertex Pharmaceuticals Incorporated | Cgrp receptor antagonists |
| EP2091533B1 (de) * | 2006-12-08 | 2012-11-28 | Merck Sharp & Dohme Corp. | Eingeschränkte spirocyclische verbindungen als cgrp-rezeptor-antagonisten |
| WO2008153849A1 (en) * | 2007-06-05 | 2008-12-18 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| JP2010529120A (ja) * | 2007-06-07 | 2010-08-26 | メルク・シャープ・エンド・ドーム・コーポレイション | 三環式アニリド複素環ｃｇｒｐ受容体アンタゴニスト |
| EP2265287B1 (de) | 2008-03-04 | 2018-09-05 | Teva Pharmaceuticals International GmbH | Verfahren zur behandlung von chronischen schmerzen |
| TW201026672A (en) * | 2008-10-07 | 2010-07-16 | Schering Corp | Spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators |
| WO2011024113A1 (en) | 2009-08-28 | 2011-03-03 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
| TWI487706B (zh) | 2010-11-12 | 2015-06-11 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| CA2836799C (en) | 2011-05-20 | 2021-05-18 | Alderbio Holdings Llc | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| TWI692485B (zh) | 2011-05-20 | 2020-05-01 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| CA3048709C (en) | 2011-05-20 | 2026-02-24 | H. Lundbeck A/S. | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| KR102448369B1 (ko) | 2014-02-05 | 2022-09-28 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| HUE065397T2 (hu) | 2014-03-21 | 2024-06-28 | Teva Pharmaceuticals Int Gmbh | Kalcitonin génekkel kapcsolatos peptid elleni antagonista antitestek és azokat alkalmazó eljárások |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| EP3366286A1 (de) | 2017-02-22 | 2018-08-29 | Johannes Keller | Verbindungen zur behandlung von sepsis |
| US12090148B2 (en) | 2020-07-29 | 2024-09-17 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JOP20210156A1 (ar) | 2019-01-08 | 2023-01-30 | H Lundbeck As | علاج إسعافي وعلاج سريع للصداع باستخدام أجسام مضادة لـ cgrp |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| MX2023007575A (es) | 2020-12-22 | 2023-09-21 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| AU2022353124A1 (en) | 2021-09-27 | 2024-04-11 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002346048A1 (en) * | 2001-06-07 | 2002-12-16 | Merck And Co., Inc. | Benzodiazepine bradykinin antagonists |
| JP4690313B2 (ja) * | 2003-03-14 | 2011-06-01 | メルク・シャープ・エンド・ドーム・コーポレイション | カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト |
| US7202251B2 (en) * | 2003-03-14 | 2007-04-10 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin CGRP receptor antagonists |
| ATE516803T1 (de) * | 2003-03-14 | 2011-08-15 | Merck Sharp & Dohme | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten |
| CA2518852A1 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Monocyclic anilide spirohydantoin cgrp receptor antagonists |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
-
2004
- 2004-03-10 EP EP04749375A patent/EP1606286B1/de not_active Expired - Lifetime
- 2004-03-10 US US10/547,228 patent/US7205293B2/en not_active Expired - Lifetime
- 2004-03-10 AU AU2004226018A patent/AU2004226018B2/en not_active Ceased
- 2004-03-10 AT AT04749375T patent/ATE509019T1/de not_active IP Right Cessation
- 2004-03-10 JP JP2006507145A patent/JP4584914B2/ja not_active Expired - Fee Related
- 2004-03-10 WO PCT/US2004/007715 patent/WO2004087649A2/en not_active Ceased
- 2004-03-10 CA CA002519515A patent/CA2519515A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004226018B2 (en) | 2009-08-27 |
| WO2004087649A2 (en) | 2004-10-14 |
| JP4584914B2 (ja) | 2010-11-24 |
| CA2519515A1 (en) | 2004-10-14 |
| EP1606286A4 (de) | 2008-08-13 |
| EP1606286B1 (de) | 2011-05-11 |
| US7205293B2 (en) | 2007-04-17 |
| AU2004226018A1 (en) | 2004-10-14 |
| EP1606286A2 (de) | 2005-12-21 |
| US20060189600A1 (en) | 2006-08-24 |
| JP2007525430A (ja) | 2007-09-06 |
| WO2004087649A3 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE509019T1 (de) | Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| ATE535514T1 (de) | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten | |
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| ATE464305T1 (de) | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
| ATE463245T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE537153T1 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
| ATE518852T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| EP1804919A4 (de) | Cgrp-rezeptorantagonisten | |
| WO2007016087A3 (en) | Heterocyclic benzodiazepine cgrp receptor antagonists | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |